


Amendments to the Specification:

Please replace paragraph [0033] of the specification with the following amended paragraph:

[0033] Most preferred are the polymeric hexamethylene biguanides, commercially available, for example, as the hydrochloride salt from Zeneca (Wilmington, Del.) sold under the trademark ~~CosmoelTM-CQ~~ COSMOCIL CQ. Such polymers and water-soluble salts are referred to as polyhexamethylene (PHMB) or polyaminoptopyl biguanide (PAPB). The term polyhexamethylene biguanide, as used herein, is meant to encompass one or more biguanides ~~have~~ having the following formula:



wherein Z, X¹ and X² are as defined above and n is from 1 to 500.

Please replace paragraph [0044] of the specification with the following amended paragraph:

[0044] The solutions employed in the present invention may also include surfactants such as a polyoxyethylene-polyoxypropylene nonionic surfactant which, for example, can be selected from the group of commercially available surfactants having the name poloxamine or poloxamer, as adopted by The CTFA International Cosmetic Ingredient Dictionary. The poloxamine surfactants consist of a poly(oxypropylene)-poly(oxyethylene) adduct of ethylene diamine having a molecular weight from about 7,500 to about 27,000 wherein at least 40 weight percent of said adduct is poly(oxyethylene), has been found to be particularly advantageous for use in conditioning contact lenses when used in amounts from about 0.01 to about 15 weight percent. Such surfactants are available from BASF Wyandotte Corp., Wyandotte, Mich., under the registered trademark ~~"Tetronic"~~ "TETRONIC". The poloxamers are an analogous series of

surfactants and are polyoxyethylene, polyoxypropylene block polymers available from BASF Wyandotte Corp., Parsippany, N.J. 07054 under the trademark "Pluronic"PLURONIC.

Please replace paragraph [0046] of the specification with the following amended paragraph:

[0046] Additional compatible surfactants that are known to be useful in contact wetting or rewetting solutions can be used in the solutions of this invention. The surfactant should be soluble in the lens care solution and non-irritating to eye tissues. Satisfactory non-ionic surfactants include polyethylene glycol esters of fatty acids, e.g. coconut, polysorbate, polyoxyethylene or polyoxypropylene ethers of higher alkanes (C_{12} - C_{18}). Examples of the preferred class include polysorbate 20 (available from ICI Americas Inc., Wilmington, Del. 19897 under the trademark Tween TWEEN® 20), polyoxyethylene (23) lauryl ether (Brij BRIJ® 35), polyoxyethylene (40) stearate (Myrj MYRJ® 52), polyoxyethylene (25) propylene glycol stearate (Atlas ATLAS® G 2612). Brij BRIJ® 35, Myrj MYRJ® 52 and Atlas ATLAS® G 2612 are trademarks of, and are commercially available from, ICI Americas Inc., Wilmington, Del. 19897.

Please replace paragraph [0049] of the specification with the following amended paragraph:

[0049] Formulations were prepared by dissolving L-histidine in water. The pH of the solutions were adjusted to 7.3 with 1N hydrochloric acid. Hydrogen peroxide, Dequest DEQUEST 2010 and polyhexamethylenebiguanide HCl (PHMB) were added to these solutions. The formulations were diluted to volume with water. Each of these solutions were tested for their activity against *C. albicans* (ATCC 10231) following a two hour exposure. The activity is expressed as a log reduction from the initial inoculum. The compositions, concentrations and activity of each of the solutions are summarized in the following table.

Log Reduction n	Preservative	Buffer	Sodium Chloride n	Hydrogen Peroxide	Dequest <u>DEQUEST</u> 2010
1.25	PHMB 0.0001%	L-histidine 0.2%	0.4%	none	0.006%
1.85	PHMB 0.0001%	L-histidine 0.2%	0.4%	0.006%	0.006%

Please replace paragraph [0051] of the specification with the following amended paragraph:

[0051] Formulations were prepared by dissolving L-histidine in water. The pH of the solutions were adjusted to 7.3 with 1N hydrochloric acid. Sodium chloride, Hydrogen peroxide, Dequest DEQUEST 2010 and polyhexamethylenebiguanide HCl (PHMB) were added to these solutions. The formulations were diluted to volume with water. Each of these solutions were tested for their activity against *C. albicans* (ATCC 10231) following a two hour exposure. The activity is expressed as a log reduction from the initial inoculum. The compositions, concentrations and activity of each of the solutions are summarized in the following table.

Log Reduction n	Preservative	Buffer	Sodium Chloride n	Hydrogen Peroxide	Dequest <u>DEQUEST</u> 2010
0.50	PHMB 0.0001%	L-histidine 0.2%	0.4%	none	0.006%
1.08	PHMB 0.0001%	L-histidine 0.2%	0.4%	0.006%	0.006%

Please replace paragraphs [0053] – [0055] of the specification with the following amended paragraph:

[0053] Formulations were prepared by dissolving L-histidine in water. The pH of the solutions were adjusted to 7.3 with 1N hydrochloric acid. Glycerin, hydrogen peroxide, ~~Dequest~~ DEQUEST 2010 and polyhexamethylenebiguanide HCl (PHMB) were added to these solutions. The formulations were diluted to volume with water. Each of these solutions were tested for their activity against *C. albicans* (ATCC 10231) following a two hour exposure. The activity is expressed as a log reduction from the initial inoculum. The compositions, concentrations and activity of each of the solutions are summarized in the following table.

Log			Hydroge		
Reduction	Preservative	Buffer	Glyceri	n	Dequest
n			n	Peroxide	<u>DEQUEST</u>
					2010
1.60	PHMB	L-Histidine	none	none	none
	0.0001%	0.2%			
2.38	PHMB	L-Histidine	none	0.006%	none
	0.0001%	0.2%			
1.27	PHMB	L-Histidine	none	none	0.006%
	0.0001%	0.2%			
2.25	PHMB	L-Histidine	none	0.006%	0.006%
	0.0001%	0.2%			
1.08	PHMB	L-Histidine	none	none	0.003%
	0.0001%	0.2%			
2.04	PHMB	L-Histidine	none	0.006%	0.003%
	0.0001%	0.2%			
1.57	PHMB	L-Histidine	0.50%	none	none
	0.0001%	0.2%			
2.15	PHMB	L-Histidine	0.50%	0.006%	none
	0.0001%	0.2%			

1.25	PHMB	L-Histidine	0.50%	none	0.006%
	0.0001%	0.2%			
2.04	PHMB	L-Histidine	0.50%	0.006%	0.006%
	0.0001%	0.2%			
1.08	PHMB	L-Histidine	0.50%	none	0.003%
	0.0001%	0.2%			
1.93	PHMB	L-Histidine	0.50%	0.006%	0.003%
	0.0001%	0.2%			

[0054] The results demonstrate the improved antifungal against *C. albicans* in each paired formulation, when 0.006% hydrogen peroxide is added. The data demonstrates that the increased activity is independent of the presence of Dequest DEQUEST 2010.

Example 4

Histidine - Peroxide

[0055] Formulations were prepared by dissolving L-histidine in water. The pH of the solutions were adjusted to 7.3 with 1N hydrochloric acid. Hydrogen peroxide, Dequest DEQUEST 2010 and polyhexamethylenebiguanide HCl (PHMB) were added to these solutions. The formulations were diluted to volume with water. Each of these solutions were tested for their activity against *C. albicans* (ATCC 10231) following a two hour exposure. The activity is expressed as a log reduction from the initial inoculum. The compositions, concentrations and activity of each of the solutions are summarized in the following table.

Log Reduction	Preservative	Buffer	Hydrogen Peroxide	Dequest <u>DEQUEST</u> 2010
------------------	--------------	--------	-------------------	-----------------------------------

2.01	PHMB 0.0001%	Histidine 0.2%	none	none
2.42	PHMB 0.0001%	Histidine 0.2%	0.006%	0.003%
0.73	Marketed Product 1			
1.95	Marketed Product 2			

Please replace paragraph [0059] of the specification with the following amended paragraph:

[0059] Formulations were prepared by dissolving L-histidine in water. The pH of the solutions were adjusted to 7.3 with 1N hydrochloric acid. Cremophor CREMOPHOR RH40, hydrogen peroxide, Dequest DEQUEST 2010 and polyhexamethylenebiguanide HCl (PHMB) were added to these solutions. The formulations were diluted to volume with water. Each of these solutions were tested for their activity against *C. albicans* (ATCC 10231) following a two hour exposure. The activity is expressed as a log reduction from the initial inoculum. The compositions, concentrations and activity of each of the solutions are summarized in the following table.

Log Reduction	Preservative	Buffer	Additive	Hydrogen Peroxide	Dequest <u>DEQUEST</u> 2010
2.51	PHMB 0.0001%	L-Histidine 0.2%	Cremophor CREMOPHOR RH 40	none	none
3.27	PHMB 0.0001%	L-Histidine 0.2%	Cremophor CREMOPHOR RH 40	0.006%	0.003%

Please replace paragraph [0061] of the specification with the following amended paragraph:

[0061] Formulations were prepared by dissolving L-histidine in water. The pH of the solutions were adjusted to 7.3 with 1N hydrochloric acid. The tonicity agent, hydrogen peroxide, Dequest DEQUEST 2010 and polyhexamethylenebiguanide HCl (PHMB) were added to these solutions. The formulations were diluted to volume with water. Each of these solutions were tested for their activity against *C. albicans* (ATCC 10231) following a two hour exposure. The activity is expressed as a log reduction from the initial inoculum. The compositions, concentrations and activity of each of the solutions are summarized in the following table.

Log Reduction	Preservative	Buffer	Tonicity Agent	Wetting Agent	Hydrogen Peroxide	Dequest <u>DEQUEST</u> 2010
2.42	PHMB 0.0001%	L-Histidine 0.2%	none	Cremophor CREMOPHOR RH 40		
3.34	PHMB 0.0001%	L-Histidine 0.2%	none	Cremophor CREMOPHOR RH 40	0.006%	0.003%
2.19	PHMB 0.0001%	L-Histidine 0.2%	glycerin 3%	Cremophor CREMOPHOR RH 40		
2.94	PHMB 0.0001%	L-Histidine 0.2%	glycerin 3%	Cremophor CREMOPHOR RH 40	0.006%	0.003%
2.19	PHMB	L-Histidine	propylene	Cremophor		

	0.0001%	0.2%	glycol 3%	CREMOPHOR RH 40		
2.95	PHMB 0.0001%	L-Histidine 0.2%	propylene glycol 3%	Cremopher CREMOPHOR RH 40	0.006%	0.003%
3.36	PHMB 0.0001%	L-Histidine 0.2%	sorbitol 5%	Cremopher CREMOPHOR RH 40		
3.92	PHMB 0.0001%	L-Histidine 0.2%	sorbitol 5%	Cremopher CREMOPHOR RH 40	0.006%	0.003%

Please replace paragraph **[0064]** of the specification with the following amended paragraph:

[0064] The data shows that the addition of 0.006% hydrogen peroxide to histidine provides increased antifungal activity against *C. albicans*. Consistent results were found in the presence of ~~Cremopher~~ CREMOPHOR RH40 with glycerin, propylene glycol, and sorbitol. All formulations with dilute hydrogen peroxide added to histidine were equal to or superior to marketed products.